Prothena Biosciences specializes in developing therapeutics for neurodegenerative and rare peripheral amyloid diseases, focusing on the biology of misfolded proteins.

Prothena Biosciences

Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).

COM:PROTHENA

Prothena Biosciences

Last Close

14.44

22/11 21:00

Market Cap

818.97M

Beta: -

Volume Today

468.84K

Avg: -

Filings Not Available